Liu, Jing http://orcid.org/0000-0002-3113-4015
Bu, Xia http://orcid.org/0000-0002-1327-9237
Chu, Chen http://orcid.org/0000-0001-8084-0867
Dai, Xiaoming
Asara, John M.
Sicinski, Piotr http://orcid.org/0000-0002-8859-5234
Freeman, Gordon J. http://orcid.org/0000-0002-7210-5616
Wei, Wenyi http://orcid.org/0000-0003-0512-3811
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253027, R01 CA236226, P01 CA250959, CA40192, P50CA101942, P50CA206963)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (P01AI56299)
Article History
Received: 29 July 2022
Accepted: 28 April 2023
First Online: 17 May 2023
Competing interests
: W.W. is a co-founder and stockholder of Rekindle Therapeutics. All other authors declare no competing interests. G.J. Freeman has patents/pending royalties on the PD-1/PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Eli Lilly, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, and Novartis. G.J. Freeman has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant, Trillium, GV20, and Geode. G.J. Freeman has equity in Nextpoint, Triursus, Xios, iTeos, IgM, GV20, and Geode. G.J. Freeman has patents on TIM-3 licensed to Novartis. P.S. has been a consultant at Novartis, Genovis, Guidepoint, The Planning Shop, ORIC Pharmaceuticals, Cedilla Therapeutics, Syros Pharmaceuticals, Exo Therapeutics, Curie Bio Operations, Exscientia, Ligature Therapeutics, Redesign Science. P.S. laboratory receives research funding from Novartis.